hotspot -WSS

hotspot

author：fashion 2025-09-02 09:38:15 - browse：1

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

WSS

Insurer loopholes limit power of law against surprise medical bills

STAT Readout: Friday, Oct. 20 biotech updates

People with mental disorders often marry others with same

The problems with dementia villages

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Roivant's CEO is a star, but biotech's black hole persists

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Study on Amgen’s bispecific immunotherapy produces positive data

Supreme Court strikes down use of affirmative action

Scientists uncover potential path to treating deadly childhood tumor

Moonlake's readout produced a cash windfall. Risks remain

Covid silver lining: Unprecedented look at human immune system

Moonlake's readout produced a cash windfall. Risks remain

Drug companies' payments and gifts affect physicians' prescribing

United colonoscopy coverage change 'may cost lives,' doctors say

Roche drug slashes death risk in early

focus

Medicare Advantage 2025 payments will dip, Biden administration says

J&J lung cancer data amount to new salvo against AstraZeneca

Mass General Brigham physicians react to latest merger step

Hundreds died while taking an arthritis drug, but nobody alerted patients

STAT Summit: Ending the crisis of Black deaths in the U.S.

Smaller biotechs seek to piggyback on weight loss drug boom

focus

focus

focus

knowledge